Top

Published in:

29-02-2024 | Pain in MS | Review Article

Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

Authors: Anastasiia D. Shkodina, Mainak Bardhan, Hitesh Chopra, Onyekachi Emmanuel Anyagwa, Viktoriia A. Pinchuk, Kateryna V. Hryn, Anzhelina M. Kryvchun, Dmytro I. Boiko, Vinay Suresh, Amogh Verma, Mykhailo Yu. Delva

Published in: CNS Drugs | Issue 3/2024

Abstract

Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte’s phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction) may be recommended for patients with neuropathic pain in multiple sclerosis. The choice of treatment depends on the severity and type of pain as well as other factors, such as patient preferences and comorbidities. There is a pressing need for healthcare professionals and researchers to prioritize the development of better strategies for managing multiple sclerosis-induced neuropathic pain.

Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172:3–13. https://doi.org/10.1016/j.neurol.2015.10.006.CrossRefPubMed

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler J. 2020;26:1816–21. https://doi.org/10.1177/1352458520970841.CrossRef

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–4. https://doi.org/10.1212/WNL.0000000000000768.CrossRefPubMedCentralPubMed

Chisari CG, Sgarlata E, Arena S, D’Amico E, Toscano S, Patti F. An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opin Pharmacother. 2020;21:2249–63. https://doi.org/10.1080/14656566.2020.1757649.CrossRefPubMed

Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis. Arch Neurol. 2003;60:1089. https://doi.org/10.1001/archneur.60.8.1089.CrossRefPubMed

O’Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137:96–111. https://doi.org/10.1016/j.pain.2007.08.024.CrossRefPubMed

Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260:351–67. https://doi.org/10.1007/s00415-012-6579-2.CrossRefPubMed

Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology. 2014;22:1–22. https://doi.org/10.1007/s10787-013-0195-3.CrossRefPubMed

Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154:632–42. https://doi.org/10.1016/j.pain.2012.12.002.CrossRefPubMed

10.

Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep. 2010;14:189–95. https://doi.org/10.1007/s11916-010-0108-8.CrossRefPubMed

11.

Feketová S, Waczulíková I, Valkovič P, Mareš J. Central pain in patients with multiple sclerosis. J Mult Scler. 2017. https://doi.org/10.4172/2376-0389.1000208.CrossRef

12.

Solaro C, Cella M, Signori A, Martinelli V, Radaelli M, Centonze D, et al. Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. J Neurol. 2018;265:828–35. https://doi.org/10.1007/s00415-018-8758-2.CrossRefPubMed

13.

Drulovic J, Basic-Kes V, Grgic S, Vojinovic S, Dincic E, Toncev G, et al. The prevalence of pain in adults with multiple sclerosis: a multicenter cross-sectional survey. Pain Med. 2015;16:1597–602. https://doi.org/10.1111/pme.12731.CrossRefPubMed

14.

Heitmann H, Haller B, Tiemann L, Mühlau M, Berthele A, Tölle TR, et al. Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain. 2020;161:787–96. https://doi.org/10.1097/j.pain.0000000000001767.CrossRefPubMed

15.

Kahraman T, Özdoğar AT, Ertekin Ö, Özakbaş S. Frequency, type, distribution of pain and related factors in persons with multiple sclerosis. Mult Scler Relat Disord. 2019;28:221–5. https://doi.org/10.1016/j.msard.2019.01.002.CrossRefPubMed

16.

Karakas H, Kaya E, Abasiyanik Z, Ozdogar AT. Investigation of neuropathic pain distribution and related factors in people with multiple sclerosis. J Mult Scler Res. 2022;2:46–51. https://doi.org/10.4274/jmsr.galenos.2022.2022-7-2.CrossRef

17.

Kasap Z, Uğurlu H. Pain in patients with multiple sclerosis. Turk J Phys Med Rehabil. 2023;1:31–9. https://doi.org/10.5606/tftrd.2022.10524.CrossRef

18.

Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007;127:35–41. https://doi.org/10.1016/j.pain.2006.07.015.CrossRefPubMed

19.

Murphy KL, Bethea Jr, Fischer R. Neuropathic pain in multiple sclerosis: current therapeutic intervention and future treatment perspectives. In: Zagon IS, McLaughlin PJ, editors. Multiple sclerosis: perspectives in treatment and pathogenesis. Brisbane: Codon Publications; 2017, p. 53–69. https://doi.org/10.15586/codon.multiplesclerosis.2017.ch4.

20.

Aboud T, Schuster NM. Pain management in multiple sclerosis: a review of available treatment options. Curr Treat Opt Neurol. 2019;21:62. https://doi.org/10.1007/s11940-019-0601-2.CrossRef

21.

Watson JC, Sandroni P. Central neuropathic pain syndromes. Mayo Clin Proc. 2016;91:372–85. https://doi.org/10.1016/j.mayocp.2016.01.017.CrossRefPubMed

22.

Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D’Aleo G, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63:919–21. https://doi.org/10.1212/01.WNL.0000137047.85868.D6.CrossRefPubMed

23.

Racke MK, Frohman EM, Frohman T. Pain in multiple sclerosis: understanding pathophysiology, diagnosis, and management through clinical vignettes. Front Neurol. 2022;12: 799698. https://doi.org/10.3389/fneur.2021.799698.CrossRefPubMedCentralPubMed

24.

Urits I, Adamian L, Fiocchi J, Hoyt D, Ernst C, Kaye AD, et al. Advances in the understanding and management of chronic pain in multiple sclerosis: a comprehensive review. Curr Pain Headache Rep. 2019;23:59. https://doi.org/10.1007/s11916-019-0800-2.CrossRefPubMed

25.

Klit H, Finnerup NB, Andersen G, Jensen TS. Central poststroke pain: a population-based study. Pain. 2011;152:818–24. https://doi.org/10.1016/j.pain.2010.12.030.CrossRefPubMed

26.

Mirabelli E, Elkabes S. Neuropathic pain in multiple sclerosis and its animal models: focus on mechanisms, knowledge gaps and future directions. Front Neurol. 2021;12: 793745. https://doi.org/10.3389/fneur.2021.793745.CrossRefPubMedCentralPubMed

27.

Browne TJ, Hughes DI, Dayas CV, Callister RJ, Graham BA. Projection neuron axon collaterals in the dorsal horn: placing a new player in spinal cord pain processing. Front Physiol. 2020;11: 560082. https://doi.org/10.3389/fphys.2020.560802.CrossRef

28.

Dworsky-Fried Z, Faig CA, Vogel HA, Kerr BJ, Taylor AMW. Central amygdala inflammation drives pain hypersensitivity and attenuates morphine analgesia in experimental autoimmune encephalomyelitis. Pain. 2022;163:e49-61. https://doi.org/10.1097/j.pain.0000000000002307.CrossRefPubMed

29.

Svendsenl KB, Sørensenl L, Jensenl TS, Hansenl HJ, Bachl FW. MRI of the central nervous system in MS patients with and without pain. Eur J Pain. 2011;15:395–401. https://doi.org/10.1016/j.ejpain.2010.09.006.CrossRef

30.

Plantone D, Vollono C, Pardini M, Primiano G, Myftari V, Vitetta F, et al. A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. Neurol Sci. 2021;42:1941–7. https://doi.org/10.1007/s10072-020-04745-3.CrossRefPubMed

31.

Doolen S, Iannitti T, Donahue RR, Shaw BC, Grachen CM, Taylor BK. Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn. Pain. 2018;159:224–38. https://doi.org/10.1097/j.pain.0000000000001106.CrossRefPubMedCentralPubMed

32.

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895–926. https://doi.org/10.1016/j.jpain.2009.06.012.CrossRefPubMedCentralPubMed

33.

Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol. 2013;74:630–6. https://doi.org/10.1002/ana.24017.CrossRefPubMed

34.

Tao Y-X. AMPA receptor trafficking in inflammation-induced dorsal horn central sensitization. Neurosci Bull. 2012;28:111–20. https://doi.org/10.1007/s12264-012-1204-z.CrossRefPubMedCentralPubMed

35.

Mao L-M, Liu X-Y, Zhang G-C, Chu X-P, Fibuch EE, Wang LS, et al. Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo. Neuropharmacology. 2008;55:403–8. https://doi.org/10.1016/j.neuropharm.2008.05.034.CrossRefPubMedCentralPubMed

36.

Tang J, Bair M, Descalzi G. Reactive astrocytes: critical players in the development of chronic pain. Front Psychiatry. 2021;12: 682056. https://doi.org/10.3389/fpsyt.2021.682056.CrossRefPubMedCentralPubMed

37.

Warfield AE, Prather JF, Todd WD. Systems and circuits linking chronic pain and circadian rhythms. Front Neurosci. 2021;15: 705173. https://doi.org/10.3389/fnins.2021.705173.CrossRefPubMedCentralPubMed

38.

Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, et al. Targeting oxidative stress mechanisms to treat Alzheimer’s and Parkinson’s disease: a critical review. Oxid Med Cell Longev. 2022;2022:1–9. https://doi.org/10.1155/2022/7934442.CrossRef

39.

Boiko DI, Shkodina AD, Hasan MM, Bardhan M, Kazmi SK, Chopra H, et al. Melatonergic receptors (Mt1/Mt2) as a potential additional target of novel drugs for depression. Neurochem Res. 2022;47:2909–24. https://doi.org/10.1007/s11064-022-03646-5.CrossRefPubMedCentralPubMed

40.

Zhuo M. Descending facilitation. Mol Pain. 2017;13:174480691769921. https://doi.org/10.1177/1744806917699212.CrossRef

41.

Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care. 2014;8:143–51. https://doi.org/10.1097/SPC.0000000000000055.CrossRefPubMedCentralPubMed

42.

Papadopoulou A, Naegelin Y, Weier K, Amann M, Hirsch J, von Felten S, et al. MRI characteristics of periaqueductal lesions in multiple sclerosis. Mult Scler Relat Disord. 2014;3:542–51. https://doi.org/10.1016/j.msard.2014.01.001.CrossRefPubMed

43.

François A, Low SA, Sypek EI, Christensen AJ, Sotoudeh C, Beier KT, et al. A brainstem-spinal cord inhibitory circuit for mechanical pain modulation by GABA and enkephalins. Neuron. 2017;93:822-39.e6. https://doi.org/10.1016/j.neuron.2017.01.008.CrossRefPubMedCentralPubMed

44.

Max MB, Hagen NA. Do changes in brain sodium channels cause central pain? Neurology. 2000;54:544–5. https://doi.org/10.1212/wnl.54.3.544.CrossRefPubMed

45.

Truini A, Galeotti F, Cruccu G. Treating pain in multiple sclerosis. Expert Opin Pharmacother. 2011;12:2355–68. https://doi.org/10.1517/14656566.2011.607162.CrossRefPubMed

46.

Nefedov OO, Kalbus OI. Mechanisms of occurrence and chronicity of neuropathic pain in multiple sclerosis in clinical and experimental conditions. Ukr Med J. 2022;147–148:7–11. https://doi.org/10.32471/umj.1680-3051.147.226789.CrossRef

47.

Morales Y, Parisi JE, Lucchinetti CF. The pathology of multiple sclerosis: evidence for heterogeneity. Adv Neurol. 2006;98:27–45.PubMed

48.

Quiton RL, Masri R, Thompson SM, Keller A. Abnormal activity of primary somatosensory cortex in central pain syndrome. J Neurophysiol. 2010;104:1717–25. https://doi.org/10.1152/jn.00161.2010.CrossRefPubMedCentralPubMed

49.

Khare S, Seth D. Lhermitte’s sign: the current status. Ann Indian Acad Neurol. 2015;18:154. https://doi.org/10.4103/0972-2327.150622.CrossRefPubMedCentralPubMed

50.

Sá MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr. 2012;70:733–40. https://doi.org/10.1590/S0004-282X2012000900016.CrossRefPubMed

51.

Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler J. 2005;11:398–402. https://doi.org/10.1191/1352458505ms1177oa.CrossRef

52.

Zhang L, Berta T, Xu Z-Z, Liu T, Park JY, Ji R-R. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain. 2011;152:419–27. https://doi.org/10.1016/j.pain.2010.11.014.CrossRefPubMed

53.

Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, et al. Trigeminal neuralgia. Neurology. 2016;87:220–8. https://doi.org/10.1212/WNL.0000000000002840.CrossRefPubMedCentralPubMed

54.

Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain. 2019;20:20. https://doi.org/10.1186/s10194-019-0969-0.CrossRefPubMedCentralPubMed

55.

Peker S, Kurtkaya Ö, Üzün İ, Pamir MN. Microanatomy of the central myelin-peripheral myelin transition zone of the trigeminal nerve. Neurosurgery. 2006;59:354–9. https://doi.org/10.1227/01.NEU.0000223501.27220.69.CrossRefPubMed

56.

Cruccu G, Biasiotta A, Di Rezze S, Fiorelli M, Galeotti F, Innocenti P, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143:186–91. https://doi.org/10.1016/j.pain.2008.12.026.CrossRefPubMed

57.

Godazandeh K, Martinez Sosa S, Wu J, Zakrzewska JM. Trigeminal neuralgia: comparison of characteristics and impact in patients with or without multiple sclerosis. Mult Scler Relat Disord. 2019;34:41–6. https://doi.org/10.1016/j.msard.2019.06.015.CrossRefPubMed

58.

Truini A, Prosperini L, Calistri V, Fiorelli M, Pozzilli C, Millefiorini E, et al. A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology. 2016;86:2094–9. https://doi.org/10.1212/WNL.0000000000002720.CrossRefPubMed

59.

Gerwin R. Chronic facial pain: trigeminal neuralgia, persistent idiopathic facial pain, and myofascial pain syndrome: an evidence-based narrative review and etiological hypothesis. Int J Environ Res Public Health. 2020;17:7012. https://doi.org/10.3390/ijerph17197012.CrossRefPubMedCentralPubMed

60.

Obermann M, Yoon M-S, Ese D, Maschke M, Kaube H, Diener H-C, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology. 2007;69:835–41. https://doi.org/10.1212/01.wnl.0000269670.30045.6b.CrossRefPubMed

61.

Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans—how symptoms help disclose mechanisms. Nat Rev Neurol. 2013;9:572–82. https://doi.org/10.1038/nrneurol.2013.180.CrossRefPubMed

62.

Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Concomitant persistent pain in classical trigeminal neuralgia: evidence for different subtypes. Headache J Head Face Pain. 2014;54:1173–83. https://doi.org/10.1111/head.12384.CrossRef

63.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. https://doi.org/10.1177/0333102417738202.

64.

Benoliel R, Svensson P, Evers S, Wang S-J, Barke A, Korwisi B, et al. The IASP classification of chronic pain for ICD-11: chronic secondary headache or orofacial pain. Pain. 2019;160:60–8. https://doi.org/10.1097/j.pain.0000000000001435.CrossRefPubMed

65.

Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain. 2013;14:37. https://doi.org/10.1186/1129-2377-14-37.CrossRefPubMedCentralPubMed

66.

Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28. https://doi.org/10.1111/j.1468-1331.2008.02185.x.CrossRefPubMed

67.

Mazhari A. Multiple sclerosis-related pain syndromes: an imaging update. Curr Pain Headache Rep. 2016;20:63. https://doi.org/10.1007/s11916-016-0594-4.CrossRefPubMed

68.

Ferraro D, Plantone D, Morselli F, Dallari G, Simone AM, Vitetta F, et al. Systematic assessment and characterization of chronic pain in multiple sclerosis patients. Neurol Sci. 2018;39:445–53. https://doi.org/10.1007/s10072-017-3217-x.CrossRefPubMed

69.

Rog D, Nurmikko T, Young C. Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29:2068–79. https://doi.org/10.1016/j.clinthera.2007.09.013.CrossRefPubMed

70.

Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–21. https://doi.org/10.1016/j.jpain.2007.12.010.CrossRefPubMedCentralPubMed

71.

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136–48. https://doi.org/10.1016/j.jpain.2012.10.009.CrossRefPubMed

72.

Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253. https://doi.org/10.1136/bmj.38149.566979.AE.CrossRefPubMedCentralPubMed

73.

Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44:S34–42 (discussion S42–3).

74.

Vakhapova V, Auriel E, Karni A. Nightly sublingual tizanidine HCl in multiple sclerosis. Clin Neuropharmacol. 2010;33:151–4. https://doi.org/10.1097/WNF.0b013e3181daad7d.CrossRefPubMed

75.

Sachais BA. Baclofen, a new antispastic drug. Arch Neurol. 1977;34:422. https://doi.org/10.1001/archneur.1977.00500190056008.CrossRefPubMed

76.

From A, Heltberg A. A double-blind trial with baclofen (Lioresal^®) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand. 2009;51:158–66. https://doi.org/10.1111/j.1600-0404.1975.tb01366.x.CrossRef

77.

Cartlidge NEF, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci. 1974;23:17–24. https://doi.org/10.1016/0022-510X(74)90137-3.CrossRefPubMed

78.

Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil. 2000;81:164–9. https://doi.org/10.1016/s0003-9993(00)90135-7.CrossRefPubMed

79.

Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med. 2004;18:5–11. https://doi.org/10.1191/0269216304pm845ra.CrossRefPubMed

80.

McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg. 1999;89:985. https://doi.org/10.1097/00000539-199910000-00030.CrossRefPubMed

81.

Harke H, Gretenkort P, Ladleif HU, Rahman S, Harke O. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Analg. 2001. https://doi.org/10.1097/00000539-200102000-00039.CrossRefPubMed

82.

Cianchetti C, Zuddas A, Randazzo AP, Perra L, Marrosu MG. Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology. 1999;53:433. https://doi.org/10.1212/WNL.53.2.433.CrossRefPubMed

83.

Vollmer TL, Robinson MJ, Risser RC, Malcolm SK. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract. 2014;14:732–44. https://doi.org/10.1111/papr.12127.CrossRefPubMed

84.

Aiyer R, Barkin RL, Bhatia A. Treatment of neuropathic pain with venlafaxine: a systematic review. Pain Med. 2016. https://doi.org/10.1093/pm/pnw261.CrossRef

85.

Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell L-H. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain. 1997;13:313–23. https://doi.org/10.1097/00002508-199712000-00009.CrossRefPubMed

86.

Wang H-Y, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin A prevents mu opioid receptor–Gs coupling underlying opioid tolerance and dependence. PLoS ONE. 2008;3: e1554. https://doi.org/10.1371/journal.pone.0001554.ADSCrossRefPubMedCentralPubMed

87.

Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010. https://doi.org/10.1002/ana.22006.CrossRefPubMed

88.

Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler J. 2008;14:1076–83. https://doi.org/10.1177/1352458508095828.CrossRef

89.

Hyman N. Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12. https://doi.org/10.1136/jnnp.68.6.707.CrossRefPubMedCentralPubMed

90.

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73. https://doi.org/10.1016/S1474-4422(14)70251-0.CrossRefPubMedCentralPubMed

91.

Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Rev Neurol (Paris). 2019;175:46–50. https://doi.org/10.1016/j.neurol.2018.08.005.CrossRefPubMed

92.

Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008;5:16–9.PubMed

93.

Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2021;10:55–68. https://doi.org/10.1007/s40122-020-00210-3.CrossRefPubMed

94.

Stamoula E, Siafis S, Dardalas I, Ainatzoglou A, Matsas A, Athanasiadis T, et al. Antidepressants on multiple sclerosis: a review of in vitro and in vivo models. Front Immunol. 2021;12: 677879. https://doi.org/10.3389/fimmu.2021.677879.CrossRefPubMedCentralPubMed

95.

American Geriatrics Society 2019 updated AGS Beers Criteria^® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94. https://doi.org/10.1111/jgs.15767

96.

Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–6. https://doi.org/10.1056/NEJM199205073261904.CrossRefPubMed

97.

Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42:135–44. https://doi.org/10.1016/0304-3959(90)91157-E.CrossRefPubMed

98.

Colombo B, Annovazzi POL, Comi G. Medications for neuropathic pain: current trends. Neurol Sci. 2006;27:s183–9. https://doi.org/10.1007/s10072-006-0598-7.CrossRefPubMed

99.

Foley P, Parker RA, de Angelis F, Connick P, Chandran S, Young C, et al. Efficacy of fluoxetine, riluzole and amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis: pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial. Mult Scler Relat Disord. 2022;63: 103925. https://doi.org/10.1016/j.msard.2022.103925.CrossRefPubMed

100.

Falah M, Madsen C, Holbech JV, Sindrup SH. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain. 2012;16:860–9. https://doi.org/10.1002/j.1532-2149.2011.00073.x.CrossRefPubMed

101.

Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6:61–8. https://doi.org/10.1053/eujp.2001.0324.CrossRefPubMed

102.

McCleane GJ. Lamotrigine in the management of neuropathic pain: a review of the literature. Clin J Pain. 2000;16:321–6. https://doi.org/10.1097/00002508-200012000-00008.CrossRefPubMed

103.

Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305. https://doi.org/10.1016/j.pain.2005.08.013.CrossRefPubMed

104.

Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24:64. https://doi.org/10.1007/s11916-020-00898-0.CrossRefPubMed

105.

Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler J. 2010;16:964–9. https://doi.org/10.1177/1352458510366857.CrossRef

106.

Kaiman S, Österberg A, Sörensen J, Boivie J, Bertler Å. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain 2002;6:69–80. https://doi.org/10.1053/eujp.2001.0307.

107.

Dworsky-Fried Z, Chadwick CI, Kerr BJ, Taylor AMW. Multiple sclerosis and the endogenous opioid system. Front Neurosci. 2021;15: 741503. https://doi.org/10.3389/fnins.2021.741503.CrossRefPubMedCentralPubMed

108.

Marrie RA, Fisk JD, Walld R, Bolton JM, Sareen J, Patten SB, et al. Prescription opioid use in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023;94:167–9. https://doi.org/10.1136/jnnp-2022-329508.CrossRefPubMed

109.

Campos RMP, Aguiar AFL, Paes-Colli Y, Trindade PMP, Ferreira BK, de Melo Reis RA, et al. Cannabinoid therapeutics in chronic neuropathic pain: from animal research to Human treatment. Front Physiol. 2021;12: 785176. https://doi.org/10.3389/fphys.2021.785176.CrossRefPubMedCentralPubMed

110.

Anand U, Pacchetti B, Anand P, Sodergren MH. Cannabis-based medicines and pain: a review of potential synergistic and entourage effects. Pain Manag. 2021;11:395–403. https://doi.org/10.2217/pmt-2020-0110.CrossRefPubMed

111.

Aborode AT, Awuah WA, Mikhailova T, Abdul- Rahman T, Pavlock S, Nansubuga EP, et al. OMICs Ttchnologies for natural compounds-based drug development. Curr Top Med Chem. 2022;22:1751–65. https://doi.org/10.2174/1568026622666220726092034.CrossRefPubMed

112.

Rudroff T, Sosnoff J. Cannabidiol to improve mobility in people with multiple sclerosis. Front Neurol. 2018;9:183. https://doi.org/10.3389/fneur.2018.00183.CrossRefPubMedCentralPubMed

113.

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–9. https://doi.org/10.1212/01.wnl.0000176753.45410.8b.CrossRefPubMed

114.

Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–63. https://doi.org/10.1212/WNL.0000000000000363.CrossRefPubMedCentralPubMed

115.

Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16:149–59. https://doi.org/10.1111/pme.12569.CrossRefPubMed

116.

Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31:569–75. https://doi.org/10.1177/0269881117699616.CrossRefPubMed

117.

Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 2018;18:8. https://doi.org/10.1007/s11910-018-0814-x.CrossRefPubMed

118.

Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs. 2010;70:2409–38. https://doi.org/10.2165/11585260-000000000-00000.CrossRefPubMed

119.

Link K, Knowles LM, Alschuler KN, Ehde DM. Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: an observational study. Mult Scler Relat Disord. 2023;75: 104742. https://doi.org/10.1016/j.msard.2023.104742.CrossRefPubMed

120.

Sirbu C-A, Georgescu R, Pleşa FC, Paunescu A, Marilena Ţânţu M, Nicolae AC, et al. Cannabis and cannabinoids in multiple sclerosis: from experimental models to clinical practice: a review. Am J Ther. 2023;30:e220–31. https://doi.org/10.1097/MJT.0000000000001568.CrossRefPubMed

121.

Hansen JS, Gustavsen S, Roshanisefat H, Kant M, Biering-Sørensen F, Andersen C, et al. Cannabis-based medicine for neuropathic pain and spasticity: a multicenter, randomized, double-blinded, placebo-controlled trial. Pharmaceuticals. 2023;16:1079. https://doi.org/10.3390/ph16081079.CrossRefPubMedCentralPubMed

122.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung H-P, Soelberg Sørensen P, Thompson AJ, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler J. 2016;22:1386–96. https://doi.org/10.1177/1352458516643600.CrossRef

123.

Di Stefano G, De Stefano G, Di Lionardo A, Cruccu G, Truini A. Pharmacotherapeutic options for managing pain in multiple sclerosis. CNS Drugs. 2020;34:749–61. https://doi.org/10.1007/s40263-020-00731-7.CrossRefPubMed

124.

Yu B, Wu K, Xu X, Liu Y, Jiang J. Recent advances in nanoplatforms for the treatment of neuropathic pain. Spinal Cord. 2022;60:594–603. https://doi.org/10.1038/s41393-021-00746-x.CrossRefPubMed

125.

Bidve P, Prajapati N, Kalia K, Tekade R, Tiwari V. Emerging role of nanomedicine in the treatment of neuropathic pain. J Drug Target. 2020;28:11–22. https://doi.org/10.1080/1061186X.2019.1587444.CrossRefPubMed

126.

Zhu Y, Yao Y, Kuang R, Chen Z, Du Z, Qu S. Global research trends of nanotechnology for pain management. Front Bioeng Biotechnol. 2023. https://doi.org/10.3389/fbioe.2023.1249667.CrossRefPubMedCentralPubMed

127.

Kuthati Y, Navakanth Rao V, Busa P, Tummala S, Davuluri Venkata Naga G, Wong CS. Scope and applications of nanomedicines for the management of neuropathic pain. Mol Pharm. 2020;17:1015–27. https://doi.org/10.1021/acs.molpharmaceut.9b01027.

128.

Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226–32. https://doi.org/10.1016/j.cell.2016.01.043.CrossRefPubMed

129.

Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano. 2014;8:2148–60. https://doi.org/10.1021/nn405033r.CrossRefPubMedCentralPubMed

130.

Pearson RM, Casey LM, Hughes KR, Wang LZ, North MG, Getts DR, et al. Controlled delivery of single or multiple antigens in tolerogenic nanoparticles using peptide-polymer bioconjugates. Mol Ther. 2017;25:1655–64. https://doi.org/10.1016/j.ymthe.2017.04.015.CrossRefPubMedCentralPubMed

131.

Belousov AN, Belousova EY, Lekomtseva YV. Prospects for the application of nanotechnology in the treatment of multiple sclerosis. Int J Clin Med Case Rep. 2023;2:1–8. https://doi.org/10.31579/2834-8664/017.CrossRef

132.

Yao L, Bojic D, Liu M. Applications and safety of gold nanoparticles as therapeutic devices in clinical trials. J Pharm Anal. 2023;13:960–7. https://doi.org/10.1016/j.jpha.2023.06.001.CrossRefPubMedCentralPubMed

133.

Chen ML, Yao L, Boger J, Mercer K, Thompson B, Jiang N. Non-invasive brain stimulation interventions for management of chronic central neuropathic pain: a scoping review protocol. BMJ Open. 2017;7: e016002. https://doi.org/10.1136/bmjopen-2017-016002.CrossRefPubMedCentralPubMed

134.

Johnson MI, Walsh DM. Continued uncertainty of TENS’ effectiveness for pain relief. Nat Rev Rheumatol. 2010;6:314–6. https://doi.org/10.1038/nrrheum.2010.77.CrossRefPubMed

135.

Kannan P, Bello UM, Winser SJ. Physiotherapy interventions may relieve pain in individuals with central neuropathic pain: a systematic review and meta-analysis of randomised controlled trials. Ther Adv Chronic Dis. 2022;13:204062232210786. https://doi.org/10.1177/20406223221078672.CrossRef

136.

Sawant A, Dadurka K, Overend T, Kremenchutzky M. Systematic review of efficacy of TENS for management of central pain in people with multiple sclerosis. Mult Scler Relat Disord. 2015;4:219–27. https://doi.org/10.1016/j.msard.2015.03.006.CrossRefPubMed

137.

Mokhtari T, Ren Q, Li N, Wang F, Bi Y, Hu L. Transcutaneous electrical nerve stimulation in relieving neuropathic pain: basic mechanisms and clinical applications. Curr Pain Headache Rep. 2020;24:14. https://doi.org/10.1007/s11916-020-0846-1.CrossRefPubMed

138.

Katirci Kirmaci Zİ, Adigüzel H, Göğremiş M, Kirmaci YŞ, İnanç Y, Tuncel BD. The effect of transcutaneous electrical nerve stimulation (TENS) and interferential currents (IFC) on pain, functional capacity, and quality of life in patients with multiple sclerosis: a randomized controlled, single-blinded study. Mult Scler Relat Disord. 2023;71: 104541. https://doi.org/10.1016/j.msard.2023.104541.CrossRefPubMed

139.

Lefaucheur J-P, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. 2020;131:474–528. https://doi.org/10.1016/j.clinph.2019.11.002.CrossRefPubMed

140.

Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S. Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol. 2020;27:445–53. https://doi.org/10.1111/ene.14110.CrossRefPubMed

141.

Aloizou A-M, Pateraki G, Anargyros K, Siokas V, Bakirtzis C, Liampas I, et al. Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis. Rev Neurosci. 2021;32:723–36. https://doi.org/10.1515/revneuro-2020-0140.CrossRefPubMed

142.

Palm U, Ayache SS, Padberg F, Lefaucheur J-P. Non-invasive brain stimulation therapy in multiple sclerosis: a review of tDCS, rTMS and ECT results. Brain Stimul. 2014;7:849–54. https://doi.org/10.1016/j.brs.2014.09.014.CrossRefPubMed

143.

Mori F, Codecà C, Kusayanagi H, Monteleone F, Buttari F, Fiore S, et al. Effects of nodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain. 2010;11:436–42. https://doi.org/10.1016/j.jpain.2009.08.011.CrossRefPubMed

144.

Ayache SS, Palm U, Chalah MA, Al-Ani T, Brignol A, Abdellaoui M, et al. Prefrontal tDCS decreases pain in patients with multiple sclerosis. Front Neurosci. 2016;10:147. https://doi.org/10.3389/fnins.2016.00147.CrossRefPubMedCentralPubMed

145.

Young J, Zoghi M, Khan F, Galea MP. The effect of transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis: randomized controlled trial. Pain Med. 2020;21:3451–7. https://doi.org/10.1093/pm/pnaa128.CrossRefPubMed

146.

Berra E, Bergamaschi R, De Icco R, Dagna C, Perrotta A, Rovaris M, et al. The effects of transcutaneous spinal direct current stimulation on neuropathic pain in multiple sclerosis: clinical and neurophysiological assessment. Front Hum Neurosci. 2019;13:31. https://doi.org/10.3389/fnhum.2019.00031.CrossRefPubMedCentralPubMed

147.

Provenzano DA, Williams JR, Jarzabek G, DeRiggi LA, Scott TF. Treatment of neuropathic pain and functional limitations associated with multiple sclerosis using an MRI-compatible spinal cord stimulator: a case report with two year follow-up and literature review. Neuromodulation Technol Neural Interface. 2016;19:406–13. https://doi.org/10.1111/ner.12409.CrossRef

148.

Lam CM, Monroe BR. Successful treatment of central pain and spasticity in patient with multiple sclerosis with dorsal column, paresthesia-free spinal cord stimulator: a case report. A&A Pract. 2019;12:308–12. https://doi.org/10.1213/XAA.0000000000000918.CrossRef

149.

Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, et al. Effects of transcranial random noise stimulation (tRNS) on affect, pain and attention in multiple sclerosis. Restor Neurol Neurosci. 2016;34:189–99. https://doi.org/10.3233/RNN-150557.CrossRefPubMed

150.

Harries AM, Mitchell RD. Percutaneous glycerol rhizotomy for trigeminal neuralgia: safety and efficacy of repeat procedures. Br J Neurosurg. 2011;25:268–72. https://doi.org/10.3109/02688697.2011.558946.CrossRefPubMed

151.

Patwardhan RV, Minagar A, Kelley RE, Nanda A. Neurosurgical treatment of multiple sclerosis. Neurol Res. 2006;28:320–5. https://doi.org/10.1179/016164106X98224.CrossRefPubMed

152.

Berk C, Constantoyannis C, Honey CR. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can J Neurol Sci/J Can Des Sci Neurol. 2003;30:220–3. https://doi.org/10.1017/S0317167100002626.CrossRef

153.

Mousavi SH, Gehling P, Burchiel KJ. The long-term outcome of radiofrequency ablation in multiple sclerosis-related symptomatic trigeminal neuralgia. Neurosurgery. 2022;90:293–9. https://doi.org/10.1227/NEU.0000000000001817.CrossRefPubMed

154.

Martin S, Teo M, Suttner N. The effectiveness of percutaneous balloon compression in the treatment of trigeminal neuralgia in patients with multiple sclerosis. J Neurosurg. 2015;123:1507–11. https://doi.org/10.3171/2014.11.JNS14736.CrossRefPubMed

155.

Noorani I, Lodge A, Vajramani G, Sparrow O. The effectiveness of percutaneous balloon compression, thermocoagulation, and glycerol rhizolysis for trigeminal neuralgia in multiple sclerosis. Neurosurgery. 2019;85:E684–92. https://doi.org/10.1093/neuros/nyz103.CrossRefPubMed

156.

Hong T, Ding Y, Yao P. Long-term efficacy and complications of radiofrequency thermocoagulation at different temperatures for the treatment of trigeminal neuralgia. Biochem Res Int. 2020;2020:1–10. https://doi.org/10.1155/2020/3854284.CrossRef

157.

Al Barim B, Lemcke L, Schwake M, Schipmann S, Stummer W. Repetitive percutaneous radiofrequency thermocoagulation for persistent idiopathic facial pain and central neuropathic pain attributed to multiple sclerosis: a retrospective monocentric analysis. Acta Neurochir (Wien). 2020;162:2791–800. https://doi.org/10.1007/s00701-020-04486-4.CrossRefPubMed

158.

Bender MT, Pradilla G, Batra S, See AP, James C, Pardo CA, et al. Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis. J Neurosurg. 2013;118:329–36. https://doi.org/10.3171/2012.9.JNS1226.CrossRefPubMed

159.

Texakalidis P, Xenos D, Karras CL, Rosenow JM. Percutaneous surgical approaches in multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis. World Neurosurg. 2021;146:342-50.e1. https://doi.org/10.1016/j.wneu.2020.11.006.CrossRefPubMed

160.

Spina A, Nocera G, Boari N, Iannaccone S, Mortini P. Efficacy of Gamma knife radiosurgery in the management of multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis. Neurosurg Rev. 2021;44:3069–77. https://doi.org/10.1007/s10143-021-01507-3.CrossRefPubMed

161.

Leduc W, Mathieu D, Adam E, Ferreira R, Iorio-Morin C. Gamma knife stereotactic radiosurgery for trigeminal neuralgia secondary to multiple sclerosis: a case-control study. Neurosurgery. 2023;93:453–61. https://doi.org/10.1227/neu.0000000000002440.CrossRefPubMed

162.

Franzini A, Tropeano MP, Olei S, De Robertis M, Rossini Z, Attuati L, et al. Gamma knife radiosurgery for the treatment of trigeminal neuralgia in patients with multiple sclerosis: a single-center retrospective study and literature review. World Neurosurg. 2021;149:e92-100. https://doi.org/10.1016/j.wneu.2021.02.074.CrossRefPubMed

163.

Serhan A, Kiwan A, Abushukair H, Yassin A. Deep brain stimulation use in treating multiple sclerosis tremor: a practical approach for meta-analyses. Mult Scler Relat Disord. 2022;58: 103491. https://doi.org/10.1016/j.msard.2022.103491.CrossRefPubMed

164.

Pereira EAC, Aziz TZ. Neuropathic pain and deep brain stimulation. Neurotherapeutics. 2014;11:496–507. https://doi.org/10.1007/s13311-014-0278-x.CrossRefPubMedCentralPubMed

165.

Naranjo C, Del Reguero L, Moratalla G, Hercberg M, Valenzuela M, Failde I. Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. Expert Rev Neurother. 2019;19:1201–9. https://doi.org/10.1080/14737175.2019.1653760.CrossRefPubMed

166.

Boiko DI, Chopra H, Bilal M, Kydon PV, Herasymenko LO, Rud VO, et al. Schizophrenia and disruption of circadian rhythms: an overview of genetic, metabolic and clinical signs. Schizophr Res. 2024;264:58–70. https://doi.org/10.1016/j.schres.2023.12.002.CrossRefPubMed

167.

Humo M, Lu H, Yalcin I. The molecular neurobiology of chronic pain-induced depression. Cell Tissue Res. 2019;377:21–43. https://doi.org/10.1007/s00441-019-03003-z.CrossRefPubMed

168.

Shkodina AD, Zhyvotovska AI, Boiko DI. Sleep and armed conflict: future complications of war in Ukraine. Rev Neurol (Paris). 2022;178:869–71. https://doi.org/10.1016/j.neurol.2022.09.002.CrossRefPubMed

169.

Boiko DI, Skrypnikov AM, Shkodina AD, Hasan MM, Ashraf GM, Rahman MH. Circadian rhythm disorder and anxiety as mental health complications in post-COVID-19. Environ Sci Pollut Res. 2022;29:28062–9. https://doi.org/10.1007/s11356-021-18384-4.CrossRef

170.

Boiko DI, Shyrai PO, Mats OV, Karpik ZI, Rahman MH, Khan AA, et al. Mental health and sleep disturbances among Ukrainian refugees in the context of Russian-Ukrainian war: a preliminary result from online-survey. Sleep Med. 2024;113:342–8. https://doi.org/10.1016/j.sleep.2023.12.004.CrossRefPubMed

171.

Wijma AJ, van Wilgen CP, Meeus M, Nijs J. Clinical biopsychosocial physiotherapy assessment of patients with chronic pain: the first step in pain neuroscience education. Physiother Theory Pract. 2016;32:368–84. https://doi.org/10.1080/09593985.2016.1194651.CrossRefPubMed

172.

Boiko DI, Kachur RV, Ajala OM, Bodnar LA, Zhyvotovska LV. Characteristics of anxiety and depressive manifestations in patients with acute myocardial infarction taking into account their personal accentuations. Azerbaijan Med J. 2021;2:25–31. https://doi.org/10.34921/amj.2021.2.004.CrossRef

173.

Abu Alhaija ES, AlDaikki A, Al-Omairi MK, Al-Khateeb SN. The relationship between personality traits, pain perception and attitude toward orthodontic treatment. Angle Orthod. 2010;80:1141–9. https://doi.org/10.2319/012710-59.1.CrossRefPubMedCentralPubMed

174.

Heitmann H, Biberacher V, Tiemann L, Buck D, Loleit V, Selter RC, et al. Prevalence of neuropathic pain in early multiple sclerosis. Mult Scler J. 2016;22:1224–30. https://doi.org/10.1177/1352458515613643.CrossRef

175.

Delva M, Skoryk K, Delva I. Predictors of neuropathic dysesthetic pain occurrence and chronification in multiple sclerosis (2-year prospective study). Acta Biomed. 2023;94:e2023229. https://doi.org/10.23750/abm.v94i6.14609.

176.

Driscoll MA, Edwards RR, Becker WC, Kaptchuk TJ, Kerns RD. Psychological interventions for the treatment of chronic pain in adults. Psychol Sci Public Interest. 2021;22:52–95. https://doi.org/10.1177/15291006211008157.CrossRefPubMed

177.

Li C, Hou W, Ding D, Yang Y, Gu S, Zhu Y. Evidence mapping based on systematic reviews of cognitive behavioral therapy for neuropathic pain. Neural Plast. 2023;2023:2680620. https://doi.org/10.1155/2023/2680620.CrossRefPubMedCentralPubMed

178.

Hayes SC. Acceptance and commitment therapy: towards a unified model of behavior change. World Psychiatry. 2019;18:226–7. https://doi.org/10.1002/wps.20626.CrossRefPubMedCentralPubMed

179.

Gromisch ES, Kerns RD, Czlapinski R, Beenken B, Otis J, Lo AC, et al. Cognitive behavioral therapy for the management of multiple sclerosis-related pain. Int J MS Care. 2020;22:8–14. https://doi.org/10.7224/1537-2073.2018-023.CrossRefPubMedCentralPubMed

180.

Ma T-W, Yuen AS-K, Yang Z. The efficacy of acceptance and commitment therapy for chronic pain. Clin J Pain. 2023;39:147–57. https://doi.org/10.1097/AJP.0000000000001096.

181.

Harrison AM, McCracken LM, Jones K, Norton S, Moss-Morris R. Using mixed methods case-series evaluation in the development of a guided self-management hybrid CBT and ACT intervention for multiple sclerosis pain. Disabil Rehabil. 2017;39:1785–98. https://doi.org/10.1080/09638288.2016.1209580.CrossRefPubMed

182.

Sadeghi-Bahmani D, Esmaeili L, Mokhtari F, Sadeghi Bahmani L, Afsharzadeh M, Shaygannejad V, et al. Effects of acceptance and commitment therapy (ACT) and mindfulness-based stress reduction (MBSR) on symptoms and emotional competencies in individuals with multiple sclerosis. Mult Scler Relat Disord. 2022;67: 104029. https://doi.org/10.1016/j.msard.2022.104029.CrossRefPubMed

183.

Hadoush H, Alawneh A, Kassab M, Al-Wardat M, Al-Jarrah M. Effectiveness of non-pharmacological rehabilitation interventions in pain management in patients with multiple sclerosis: systematic review and meta-analysis. NeuroRehabilitation. 2022;50:347–65. https://doi.org/10.3233/NRE-210328.CrossRefPubMed

184.

Kubsik A, Klimkiewicz P, Klimkiewicz R, Janczewska K, Woldańska-Okońska M. Rehabilitation in multiple sclerosis. Adv Clin Exp Med. 2017;26:709–15. https://doi.org/10.17219/acem/62329.

185.

Amatya B, Khan F, Galea M. Rehabilitation for people with multiple sclerosis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2019;1:CD012732. https://doi.org/10.1002/14651858.CD012732.pub2.

186.

Halabchi F, Alizadeh Z, Sahraian MA, Abolhasani M. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol. 2017;17:185. https://doi.org/10.1186/s12883-017-0960-9.CrossRefPubMedCentralPubMed

187.

Hasanpour DA. Influence of yoga and aerobics exercise on fatigue, pain and psychosocial status in patients with multiple sclerosis: a randomized trial. J Sports Med Phys Fitness. 2016;56:1417–22.

188.

Demaneuf T, Aitken Z, Karahalios A, Leong TI, De Livera AM, Jelinek GA, et al. Effectiveness of exercise interventions for pain reduction in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Arch Phys Med Rehabil. 2019;100:128–39. https://doi.org/10.1016/j.apmr.2018.08.178.CrossRefPubMed

189.

Hughes C, Smyth S, Lowe-Strong A. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial. Mult Scler J. 2009;15:1329–38. https://doi.org/10.1177/1352458509345916.CrossRef

190.

Archer KR, Coronado RA, Wegener ST. The role of psychologically informed physical therapy for musculoskeletal pain. Curr Phys Med Rehabil Rep. 2018;6:15–25. https://doi.org/10.1007/s40141-018-0169-x.CrossRef

191.

Coronado RA, Brintz CE, McKernan LC, Master H, Motzny N, Silva FM, et al. Psychologically informed physical therapy for musculoskeletal pain: current approaches, implications, and future directions from recent randomized trials. Pain Rep. 2020;5: e847. https://doi.org/10.1097/PR9.0000000000000847.CrossRefPubMedCentralPubMed

Title: Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis
Authors: Anastasiia D. Shkodina
Mainak Bardhan
Hitesh Chopra
Onyekachi Emmanuel Anyagwa
Viktoriia A. Pinchuk
Kateryna V. Hryn
Anzhelina M. Kryvchun
Dmytro I. Boiko
Vinay Suresh
Amogh Verma
Mykhailo Yu. Delva
Publication date: 29-02-2024
Publisher: Springer International Publishing
Keywords: Pain in MS
Multiple Sclerosis
Neuropathic Pain
Trigeminal Neuralgia
Neurologic Therapy
Therapy in Internal Medicine
Published in: CNS Drugs / Issue 3/2024
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-024-01072-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis

Unmet Needs in Psychodermatology: A Narrative Review

Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data

Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study